Ivermectin may inhibit LPS-induced production of inflammatory cytokines by blocking NF-kB pathway and improve LPS-induced survival in mice. FDA-approved antiparasitic drug, could potentially be used in combination with chemotherapeutic agents to treat cancers. (Noori et al., 2023; Jiang et al., 2019; Zhang et al., 2008). This evidence concerns the gene NFKB1 and cancer.